The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina.
Eur Rev Med Pharmacol Sci
; 16(12): 1611-36, 2012 Nov.
Article
em En
| MEDLINE
| ID: mdl-23161033
ABSTRACT
Ischemic heart disease (IHD) is a major cause of death in Western Countries and accounts for very high costs worldwide. In this review we discussed the pathogenesis, symptoms, diagnosis, prognosis and management of chronic IHD. In particular, we discussed about the percutaneous coronary interventions and coronary artery bypass grafting, as well as to clinical trials that evaluated the advantages of one approach versus another. Pharmacological treatment is among major objectives of the review and for each class of therapeutic agents an evaluation of well-conducted clinical trials is provided. The most important drug classes in IHD treatment are betablockers, calcium channel blockers, nitrates, antiplatelet agents, and ACE-inhibitors. In addition to these agents, also new treatment options are evaluated in patients with stable IHD. Ranolazine, in particular, is a innovative anti-anginal drug with a great successful in the management of patients with refractory angina. A pharmacological as well as clinical profile of this drug is provided.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Isquemia Miocárdica
/
Gerenciamento Clínico
/
Angina Estável
/
Acetanilidas
Limite:
Humans
Idioma:
En
Revista:
Eur Rev Med Pharmacol Sci
Assunto da revista:
FARMACOLOGIA
/
TOXICOLOGIA
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Itália